Former Senior FDA Official Joins Board as Company Prepares to Initiate Historic Phase 3b ALS Trial Under Special Protocol Assessment
$2.4 Million in H1 2026 Capital Raises Ahead of Phase 3b ENDURANCE Trial
NEW YORK , May 15, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial...
Strategic $2.0 million post year-end financing and re-rating of BCLI shares underscore market confidence
NEW YORK , Feb. 26, 2026 /PRNewswire/ --Â Brainstorm Cell Therapeutics Inc. (OTCQB:Â BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has...
NEW YORK , Feb. 20, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB:Â BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has...
NEW YORK , Nov. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial...
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.